Schroder Real Estate Investment Trust Ltd · LSE:SREI

Schroder Real Estate Investment Trust — Schroders Capital Global Innovation Trust — Investor Presentation (March 2024)

39 slides from Schroder Real Estate Investment Trust's investor presentation, March 2024

  1. Slide 1: Schroders Capital Global Innovation Trust PLC: Annual Report 2023 Investment update

    March 2024 SCHRODERS CAPITAL GLOBAL INNOVATION TRUST PLC Annual Report and Accounts 2023: Investment update Tim Creed and Harry Raikes Portfolio Managers Marketing material.

  2. Slide 2: Portfolio Managers Biographies

    Tim Creed Lead Portfolio Manager – Tim Creed is Head of Private Equity Investments at Schroders Capital. Tim is a member of Schroders Capital Private Equity Management Committee and a member of the Investment Committee. He is also on the advisory board of several leading European buyout and turnarou

  3. Slide 3: Contents

    CONTENTS 01 02 03 04 Financial Market and Outlook Appendix performance strategic update 3

  4. Slide 4: Key messages

    Key messages 2023 was a difficult year impacted by the market environment, clinical milestones, fundraising terms and the valuation environment for loss-making listed companies However, there are signs for optimism with new investments contributing to a 7.9% increase in NAV per share in the fourth q

  5. Slide 5: Delivering against our strategic priorities

    Delivering against our strategic priorities Support business growth Maximise sales Execute Complete new investments and profitability proceeds the buyback Work closely with portfolio company Maximise the sale proceeds from Rebalance the portfolio ensuring the Complete new investments that align mana

  6. Slide 6: Schroders Capital investments

    Schroders Capital investments Our portfolio is taking shape Sector Country Initial investment Growth Revolut Financials UK August 2021 Ada Health Health Care Germany December 2021 Back Market Consumer France December 2021 AgroStar Consumer India January 2023 Bizongo Business Services India September

  7. Slide 7: Financial Performance

    01 FINANCIAL PERFORMANCE 7

  8. Slide 8: Financial performance

    Financial performance As at 31 December 2023 Past performance is not a guide to future performance and may not be repeated. The value of investments and the income from them may go down as well as up and investors may not get back the amounts originally invested. Exchange rate changes may cause the

  9. Slide 9: INOV private equity strategy comprised of three sub-strategies

    INOV private equity strategy comprised of three sub-strategies LIFE SCIENCES VENTURE GROWTH ‒ Focused on more mature growth-stage companies ‒ Focused on biotech and life science opportunities. ‒ Focused on venture-stage companies with early that have achieved scaled revenues. ‒ Either clinical stage

  10. Slide 10: Calendar year performance

    Calendar year performance Past performance is not a guide to future performance and may not be repeated. The value of investments and the income from them may go down as well as up and investors may not get back the amounts originally invested. Exchange rate changes may cause the value of any overse

  11. Slide 11: 2023 net asset value performance attribution

    2023 net asset value performance attribution Notable impact in Q4 2023 Past performance is not a guide to future performance and may not be repeated. The value of investments and the income from them may go down as well as up and investors may not get back the amounts originally invested. Exchange r

  12. Slide 12: Portfolio as at 31 December 2023

    Portfolio as at 31 December 2023 Company Sector Strategy Fair value (£m) NAV (%) Oxford Nanopore Health Care Public 41.7 19.2% Breakdown by type1 Breakdown by strategy/stage1 Atom Bank Financials Growth 23.1 10.6% HPET Fund Industrials Growth 10.9 5.0% 15% Reaction Engines Industrials Venture 10.6 4

  13. Slide 13: Large positions with clinical milestones impacted performance

    Large positions with clinical milestones impacted performance Fair value Investment result in 31/12/2022 31/12/2023 % – Share price increased 239% over 2023 (USD) reflecting encouraging results from clinical trials and pipeline developments – In May and December 2023, Autolus presented positive resu

  14. Slide 14: Case study: Kymab work reaps rewards

    Case study: Kymab work reap rewards First milestone hit acquired by for an upfront payment of c. $1 .1bn and milestone payments of up to $350m Background: Potential for additional – Kymab is a clinical-stage biopharmaceutical company developing human monoclonal antibodies with a contingent payments

  15. Slide 15: Positive contribution from completed exits

    Positive contribution from completed exits Fair value Investment result in 31/12/2022 31/12/2023 % Venture Tession 3.9 - +32% – Acquisition by Proofpoint led to the Company receiving sale proceeds of £5.2m in December 2023 – In December 2023, Carmot entered into a definitive agreement to be acquired

  16. Slide 16: Encouraging development of life science investments

    Encouraging development of life science investments Clinical – Clinical – Lead candidate/ Application for Holding Indication Discovery Pre-clinical pre proof of post proof of Approval product market approval concept concept CT-388 Obesity Abelacimab Thrombosis prevention IOA-244 Uveal melanoma Anti-

  17. Slide 17: Short-term impact from funding rounds

    Short-term impact from funding rounds Fair value Investment result in 31/12/2022 31/12/2023 % – In November 2023, Atom Bank raised £100 million in new equity capital from existing shareholders BBVA, Toscafund and Infinity Investment Partners, to accelerate lending and balance sheet growth as the ban

  18. Slide 18: Market approach

    Market approach Fair value Investment result in 31/12/2022 31/12/2023 % – This reflects a mixed year in which underlying financial growth was insufficient to offset pessimistic Public Equity Oxford Nanopore 56.5 41.7 (14%) market sentiment and continued valuation weakness. – More details on next sli

  19. Slide 19: ONT: Summary of latest developments

    ONT: Summary of latest developments 2023 & 2024 YTD 1. Capital Markets Day (October 2023) 3. FY23 Preliminary Results (March 2024) Strategic investment from bioMerieux Detailed extended losses – bioMerieux, a strategic partner, is a leading company in the field of in vitro diagnostics – Adj. EBITDA

  20. Slide 20: Market & Strategic Update

    02 MARKET & STRATEGIC UPDATE 20

  21. Slide 21: Pricing pressure in late-stage VC

    Pricing pressure in late-stage VC Shift in sentiment from late to early stage and from Asia to Europe Past performance is not a guide to future performance and may not be repeated. The value of investments and the income from them may go down as well as up and investors may not get back the amounts

  22. Slide 22: Global IPO & M&A activity has decreased since Q4 2021

    Global IPO1 & M&A2 activity has decreased since Q4 2021 Challenging exit environment for the portfolio M&A deals IPOs 3,500 350 3,000 300 2,500 250 2,000 200 1,500 150 1,000 100 500 50 0 0 Q1 2019 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2021 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2019 2019 2020 2020 2020 2020 2021 2

  23. Slide 23: Schroders Capital investments

    Schroders Capital investments Our portfolio is taking shape Sector Country Initial investment Growth Revolut Financials UK August 2021 Ada Health Health Care Germany December 2021 Back Market Consumer France December 2021 AgroStar Consumer India January 2023 Bizongo Business Services India September

  24. Slide 24: New investments increasing as a proportion of the portfolio

    New investments increasing as a proportion of the portfolio Driven by new investments and disappointing performance of other holdings Total investments (£m)1 Net asset value (£m) 500 35% 500 50% 450 30% % of NAV in new investments and cash 400 400 40% 350 25% 300 300 30% 20% £m 250 15% £m 200 200 20

  25. Slide 25: New investment: AgroStar

    New investment: AgroStar One of India’s foremost AgTech start-ups Transaction details $40m financing round led by Schroders Capital with participation from Transaction Accel, Chiratae Ventures, Bertelsmann India Investments, Rabo Frontier Size Ventures, British International Investments and IFC $8.0

  26. Slide 26: New investment: Bizongo

    New investment: Bizongo India-based vendor digitisation company Transaction details $50 million series E funding round led by Schroders Capital with Transaction participation from other investors including IFC, BCap, Chiratae Ventures, Size and British International Investment $8.0 million (£6.3 mil

  27. Slide 27: New investment: Carmot Therapeutics

    New investment: Carmot Therapeutics Experimental therapeutics to treat metabolic diseases Transaction details Transaction Co-investment in Series E alongside i.a. , TCG and 5AM ventures Size $1.7 million (£1.4 million) Date Q2 2023 Best-in-class products/services/technology ✓ Strategy Life sciences

  28. Slide 28: New investment: Memo Therapeutics

    New investment: Memo Therapeutics Develops novel therapeutic antibodies for patients with viral infections and cancer Transaction details Transaction CHF 25 million series C financing round, led by Pureos Bioventures. Size CHF 0.9 million (£0.8 million) Date Q4 2023 Best-in-class products/services/t

  29. Slide 29: New investment: Securiti

    New investment: Securiti Pioneer of the Data Command Center, a centralized platform that enables the safe use of data and GenAI Transaction details Size $5.0 million (£3.9 million) Date Q4 2023 Strategy Venture Best-in-class products/services/technology ✓ Geography US Background Significant growth p

  30. Slide 30: New investment: AI software company (MMC SPV 3 LP)

    New investment: AI software company (MMC SPV 3 LP) Early leader in an emerging segment of AI software Transaction details Investment through co-investment partner MMC Ventures, Transaction via a single asset fund, MMC SPV 3 LP Size $2.0 million (£1.7 million) Best-in-class products/services/technolo

  31. Slide 31: Outlook

    03 OUTLOOK 31

  32. Slide 32: Our strategic priorities as Investment Manager

    Our strategic priorities as Investment Manager Support business growth Maximise sales Execute Complete new investments and profitability proceeds the buyback Work closely with portfolio company Maximise the sale proceeds from Rebalance the portfolio ensuring the Complete new investments that align m

  33. Slide 33: Key messages

    Key messages 2023 was a difficult year impacted by the market environment, clinical milestones, fundraising terms and the valuation environment for loss-making listed companies However, there are signs for optimism with new investments contributing to a 7.9% increase in NAV per share in the fourth q

  34. Slide 34: Appendix

    04 APPENDIX 34

  35. Slide 35: Schroders Capital Global Innovation invests in themes

    Schroders Capital Global Innovation invests in 8 themes Thematic approach based on identified long-term trends Artificial Cybersecurity Fintech/Payments Consumer Intelligence – Software using large language – Prevention, remediation, and – Processing & APIs – Marketplaces models monitoring software

  36. Slide 36: What are we looking for in portfolio companies?

    What are we looking for in portfolio companies? Seeking out ground-breaking companies Best-in-class Significant growth Managed by Investing alongside, products/services/ potential, a world-class high quality, value- technology underpinned by management team add co-investors secular trends Continued

  37. Slide 37: Portfolio outlook by strategy

    Portfolio outlook by strategy Private Equity Public Equity Life Sciences Venture Growth Venture portfolio is where, by design, we Public equity portfolio is expected to remain Several biotech companies to experience Growth portfolio is expected to benefit from expect to see the highest level of risk

  38. Slide 38: Risk considerations

    Risk considerations Schroders Capital Global Innovation Trust plc – Risk Considerations Long-term outcomes are more binary – extremely attractive rewards for success but some businesses will inevitably fail to fulfil their potential and this may expose investors to the risk of capital losses. As it

  39. Slide 39: Important Information

    Important Information Marketing material. The views and opinions contained herein are those of the authors as at the date of publication and are subject to change due to market and other conditions. Such views and opinions may not necessarily represent those expressed or reflected in other Schroders

Schroders Capital Global Innovation Trust — Investor Presentation (March 2024) on 6ix